Antioxidant status and APOE genotype as susceptibility factors for neurodegeneration in alzheimer's disease and vascular dementia

Rejuvenation Research

Volumn 16, Issue 1, 2013, Pages 51-56

  Zito, Giancarlo ^a,b   Polimanti, Renato ^c   Panetta, Valentina ^d,e   Ventriglia, Mariacarla ^d,f   Salustri, Carlo ^b   Siotto, Maria Cristina ^g   Moffa, Filomena ^d   Altamura, Claudia ^f   Vernieri, Fabrizio ^f   Lupoi, Domenico ^d   Cassetta, Emanuele ^d   Rossini, Paolo M ^a,h   Squitti, Rosanna ^d,f  

^a Casa di Cura San Raffaele Cassino   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^e L'altrastatistica srl Consultancy and Training Biostatistics Office   (Italy)

^f UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^g IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^h CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN E; APOLIPOPROTEIN E4;

AGED; ALGORITHM; ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CONTROLLED STUDY; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMEOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK; WHITE MATTER;

AGED; ALZHEIMER DISEASE; ANTIOXIDANTS; APOLIPOPROTEINS E; DEMENTIA, VASCULAR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE;

EID: 84874279735     PISSN: 15491684     EISSN: 15578577     Source Type: Journal    
DOI: 10.1089/rej.2012.1383     Document Type: Article

References (54)

1. Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: Diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55: 967-972.
2. van de Pol LA, Verhey F, Frisoni GB, et al. White matter hyperintensities and medial temporal lobe atrophy in clinical subtypes of mild cognitive impairment: The DESCRIPA study. J Neurol Neurosurg Psychiatry 2009;80:1069-1074.
3. O'Brien JT, Erkinjuntti T, Reisberg B, et al. Vascular cognitive impairment. Lancet Neurol 2003;2:89-98.
4. Enzinger C, Fazekas F, Matthews PM, et al. Risk factors for progression of brain atrophy in aging: Six-year follow-up of normal subjects. Neurology 2005;64:1704-1711.
5. Yip AG, McKee AC, Green RC, et al. APOE, vascular pathology, and the AD brain. Neurology 2005;65:259-265.
6. Bastos-Leite AJ, van der Flier WM, van Straaten EC, et al. The contribution of medial temporal lobe atrophy and vascular pathology to cognitive impairment in vascular dementia. Stroke 2007;38:3182-3185.
7. Moorhouse P, Rockwood K. Vascular cognitive impairment: Current concepts and clinical developments. Lancet Neurol 2008;7:246-255.
8. Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: The Framingham Offspring Study. Stroke 2010;41:600-606.
9. de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 2004;3:184-190.
10. Prins ND, van Dijk EJ, den Heijer T, et al. Cerebral white matter lesions and the risk of dementia. Arch Neurol 2004; 61:1531-1534.
11. Berr C, Balansard B, Arnaud J, et al. Cognitive decline is associated with systemic oxidative stress: The EVA study. Etude du Vieillissement Arteriel. J Am Geriatr Soc 2000;48: 1285-1291.
12. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-1222.
13. Piacentini S, Polimanti R, Squitti R, et al. GSTO1*E155del polymorphism associated with increased risk for late-onset Alzheimer's disease: association hypothesis for an uncommon genetic variant. Neurosci Lett 2012;506:203-207.
14. Piacentini S, Polimanti R, Squitti R, et al. GSTM1 null genotype as risk factor for late-onset Alzheimer's disease in Italian patients. J Neurol Sci 2012;317:137-140.
15. Perkins AJ, Hendrie HC, Callahan CM, et al. Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. Am J Epidemiol 1999;150:37-44.
16. Ang LS, Cruz RP, Hendel A, Granville DJ. Apolipoprotein E, an important player in longevity and age-related diseases. Exp Gerontol 2008;43:615-622.
17. McKay GJ, Silvestri G, Chakravarthy U, et al. Variations in apolipoprotein E frequency with age in a pooled analysis of a large group of older people. Am J Epidemiol 2011;173: 1357-1364.
18. Seripa D, D'Onofrio G, Panza F, et al. The genetics of the human APOE polymorphism. Rejuvenation Res 2011;14: 491-500.
19. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996;14:55-61.
20. Zappasodi F, Salustri C, Babiloni C, et al. An observational study on the influence of the APOE-epsilon4 allele on the correlation between 'free' copper toxicosis and EEG activity in Alzheimer disease. Brain Res 2008;1215:183-189.
21. Wood WG, Igbavboa U, Muller WE, Eckert GP. Cholesterol asymmetry in synaptic plasma membranes. J Neurochem 2011;116:684-689.
22. Radak Z, Zhao Z, Goto S, Koltai E. Age-associated neurodegeneration and oxidative damage to lipids, proteins and DNA. Mol Aspects Med 2011;32:305-315.
23. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
24. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43: 250-260.
25. Squitti R, Pasqualetti P, Polimanti R, et al. Metal-score as a potential non-invasive diagnostic test for Alzheimer's disease. Curr Alzheimer Res, October 2, 2012; PMID:23036026.
26. Squitti R, Salustri C, Siotto M, et al. Ceruloplasmin/transferrin ratio changes in Alzheimer's disease. Int J Alzheimers Dis 2010; doi:10.4061/2011/ 231595.
27. Scheltens P, Launer LJ, Barkhof F, et al. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: Interobserver reliability. J Neurol 1995;242:557-560.
28. Frisoni GB, Henneman WJ, Weiner MW, et al. The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. Alzheimer's Dement 2008;4:255-264.
29. Erkinjuntti T, Inzitari D, Pantoni L, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000;59:23-30.
30. Squitti R, Pasqualetti P, Dal Forno G, et al. Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 2005;64:1040-1046.
31. Miller NJ, Rice-Evans C, Davies MJ, et al. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci (Lond) 1993;84:407-412.
32. Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. Methods Enzymol 1994;234:279-293.
33. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
34. Pearson K. On lines and planes of closest fit to systems of points in space. Philosophical Magazine 1901;2:559-572.
35. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006;443:780-786.
36. Gruz P, Shimizu M. Origins of age-related DNA damage and dietary strategies for its reduction. Rejuvenation Res 2010;13:285-287.
37. Puertas MC, Martinez-Martos JM, Cobo MP, et al. Plasma oxidative stress parameters in men and women with early stage Alzheimer type dementia. Exp Gerontol 2012;47:625-630.
38. Vural H, Demirin H, Kara Y, et al. Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer's disease. J Trace Elem Med Biol 2010;24:169-173.
39. Padurariu M, Ciobica A, Hritcu L, et al. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 2010;469:6-10.
40. Torres LL, Quaglio NB, de Souza GT, et al. Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease. J Alzheimer Dis 2011;26:59-68.
41. Squitti R, Ghidoni R, Scrascia F, et al. Free copper distinguishes mild cognitive impairment subjects from healthy elderly individuals. J Alzheimer Dis 2011;23:239-248.
42. Gironi M, Bianchi A, Russo A, et al. Oxidative imbalance in different neurodegenerative diseases with memory impairment. Neurodegener Dis 2011;8:129-137.
43. Tayler H, Fraser T, Miners JS, et al. Oxidative balance in Alzheimer's disease: Relationship to APOE, Braak tangle stage, and the concentrations of soluble and insoluble amyloid-beta. J Alzheimer Dis 2010;22:1363-1373.
44. Talarowska M, Galecki P, Maes M, et al. Total antioxidant status correlates with cognitive impairment in patients with recurrent depressive disorder. Neurochem Res 2012;37: 1761-1767.
45. Gur M, Elbasan Z, Yildiray Sahin D, et al. DNA damage and oxidative status in newly diagnosed, untreated, dipper and non-dipper hypertensive patients. Hypertens Res 2012; doi: 10.1038/hr.2012.156.
46. Kharrazi H, Vaisi-Raygani A, Rahimi Z, et al. Association between enzymatic and non-enzymatic antioxidant defense mechanism with apolipoprotein E genotypes in Alzheimer disease. Clin Biochem 2008;41:932-936.
47. Devore EE, Grodstein F, van Rooij FJ, et al. Dietary antioxidants and long-term risk of dementia. Archives Neurol 2010;67:819-825.
48. Altamura C, Squitti R, Pasqualetti P, et al. Ceruloplasmin/transferrin system is related to clinical status in acute stroke. Stroke 2009;40:1282-1288.
49. Provias J, Jeynes B. Correlation analysis of capillary APOE, VEGF and eNOS expression in Alzheimer brains. Curr Alzheimer Res 2011;8:197-202.
50. Thal DR, Papassotiropoulos A, Saido TC, et al. Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer's disease. Acta Neuropathol 2010;120:169-183.
51. Attems J, Yamaguchi H, Saido TC, Thal DR. Capillary CAA and perivascular Abeta-deposition: Two distinct features of Alzheimer's disease pathology. J Neurol Sci 2010;299:155-162.
52. Shimano H, Ishibashi S, Murase T, et al. Plasma apolipoproteins in patients with multi-infarct dementia. Atherosclerosis 1989;79:257-260.
53. Betard C, Robitaille Y, Gee M, et al. Apo E allele frequencies in Alzheimer's disease, Lewy body dementia, Alzheimer's disease with cerebrovascular disease and vascular dementia. Neuroreport 1994;5:1893-1896.
54. Bennet AM, Di Angelantonio E, Ye Z, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007;298:1300-1311.